Corden Pharma - A Full-Service CDMO’s Post

The LNP starter kits are meant to facilitate easy formulation screening, enabling the generation of LNPs capable of providing efficient transfection in different cell types, including immortalized and/or primary cell cultures. The kits, which can be used for animal in-vivo applications including PK/PD studies and mRNA transfection efficacy POC/studies, have been tested in our LNP manufacturing site with GFP-mRNA as cargo, and successfully implemented for synthetic RNAs (such as siRNA) and DNA as well. The LNP Kits consist of both well-known and characterized formulations in a preclinical and clinical setting, (e.g. COVID-19 Vaccines), with various combinations available to benchmark / compare LNP formulations or create completely novel compositions that elevate formulations to the next level during screening phases. #mRNA #Lipids #vaccines #CordenPharma #Innovation #LNP #COVID

Peptide-based therapeutics are gaining significant attention in the pharmaceutical industry due to their high receptor potency and selectivity, leading to excellent drug safety and efficacy profiles. These features make endogenous peptides an ideal starting point for novel peptide therapeutics development. However, native unmodified peptides face limitations such as short systemic half-life and unfavorable physicochemical properties. The early phases of drug discovery focus on enhancing candidate molecules through chemical structure modifications and rational design. Mathematical models like quantitative structure-activity relationship (QSAR) play a crucial role in guiding drug design when larger data sets are available. QSAR models have been instrumental in the development of small molecule therapeutics, aiding in the discovery of novel binders. #Pharmaceuticals #DrugDiscovery #PeptideTherapeutics #QSAR #PharmaIndustry

Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics: DUBLIN, Dec. 22, 2023 /PRNewswire/ -- The "Biologics Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. Revenue for the Biologics Market is forecast to surpass US$470 billion in 2024, with strong revenue growth through to 2034. Advances in Regenerative Medicine...

Book your meeting with the world’s experts in peptide manufacturing in Basel!

Check out our new VIDEO: https://lnkd.in/dBjixNmN about Vertex Pharmaceuticals and it's stock price! From pioneering cystic fibrosis treatments to their newest gene-editing therapy Casgevy, find out why Vertex might be the hidden gem in biotech. #vertex #pharmaceuticals #stockstowatch

For all those #glycan enthusiasts, check out this robust work from Navin Rauniyar at Tanvex Biopharma, comparing analytical methods to characterize N-glycans on antibodies. Understanding monoclonal antibody glycosylation—a key quality attribute for biopharmaceuticals, great work team! #biotherapeutics #CDMO #dataanalysis

Want glycan analysis method expertise? In this video, our Navin Rauniyar discusses his recently published study. Check it out! #proteinsciences #protein #groundbreaking #biotech #CDMO #analyticaldevelopment #glycananalysis

🤝 Windtree Therapeutics, Inc. recently announced that the European Patent Office has granted Patent No. 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates. The pure SERCA2a Activators are one of two families of preclinical drug candidates that act on SERCA2a in the Company’s pipeline. The pure SERCA2a Activators are devoid of action on the Na+/K+ pump while activating SERCA2a. 🔎 Leveraging our Patent Analytics module, we have identified that Windtree Therapeutics, Inc. is the one of the top patent assignees treating cardiovascular disorders by targeting SERCA2a Activator. 💡 GlobalData #Patent module delivers specialized expertise in the #pharmaceutical industry, harnessing our unique #data, #insights, and #analytics. Our tailored approach and deliverables empower you with comprehensive answers to your specific patent-related questions. To learn more about our Patent capabilities or to have a chat, just drop us an 📧 email at [email protected] or ☎ contact us here>>> https://lnkd.in/deGad__f and we will get in touch! #cardiovascular #SERCA2a #drugpipeline #cardiovasculardiseases

Thoughts on this? >> Incyte drops four early-stage programs from its pipeline as part of strategic review >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #productmarketing

Thoughts on this? >> FDA places partial hold on BioNTech-MediLink ADC after multiple deaths >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare